Category: Health

Mumbai (Maharashtra) [India], June 17: COVID-19 pandemic revealed the gaps in the existing healthcare structure and showed that the Indian healthcare system is too weak.

With a lower doctor-patient ratio (1:1000), issues in last-mile healthcare delivery, and lack of qualified doctors in rural & semi-urban areas, the Indian HealthCare system needs a revolution.

There is no effective, trusted single window for healthcare delivery to everyone and no proven way for professionals to find, consult, transact with each other online.

Providing a solution to all these issues, JK Singha, Rk Ningthem, Nilesh Bhanushali, and Chittaranjan Mishra started HealWell24.

In Jan 2021, Anil Va Verma, a top executive in a major beauty care startup, joined HealWell24 as Chief Investment Officer.

The idea behind the next chapter of HealWell24 emanates from a deep and personal experience of the team.

It is to solve for the current asymmetry of Indian Healthcare (of information & access), no booking engine (such as HealWell24.com or Practo.com) will ever be sufficient at a scale, which has become obvious to the entire world during the two waves of the Covid-19 pandemic.

It would need a simple engine and a user-managed network of Doctors and Patients, owned and moderated with the community at its center stage.

DocsCampus.com, the upcoming product of HealWell24, plans to solve exactly this in a simple to use and effective platform for the next generation, stated the founder.

The Healthtech startup currently provides an easy-to-use web and mobile platform where members can connect with India’s top doctors – 24/7, 365 days a year.

Speaking about the platform, JK Singha says, “HealWell24, the current product, already empowers individuals with remote screening, where patients can connect with their dedicated doctors anytime, from anywhere, and engage in live video sessions. We also provide additional support, like doctor home visits, home lab tests, or medicine delivery, to our customers- all of which are fulfilled on the same day by our team. But with DocsCampus, we would consider us successful when we have removed the existing asymmetry of access & information for doctors or medical students in rural/ semi-urban areas & their patients.

Although the DocsCampus portal is not expected to be monetized in the coming quarters, till it hits an inflection point, the services of the current booking engine will be deeply integrated to ensure top quality service delivery to all the doctors on the platform and their patients.

The company will be moving into the next phases of DocsCampus lifecycle in the coming three quarters from launch, of which I remain tightlipped but extremely excited about.”

Operational in 35 cities, HealWell24 has 1000+ doctors, 300+ Labs, and 100+ Dentists on its platform. The startup has Apollo Spectra, Indian Oil, Hiranandani Hospital, Mahindra Lifespaces, Synechron technologies, Zeno Health as Corporate Clients, and several well-established companies in diagnostics chains & hospitals as partners.

Till now, HealWell24 has provided essential healthcare service to thousands of Indians for conditions such as bone cancer, dental abscesses, and diabetic retinopathy.

With over 215K consumer transacted so far, HealWell24 currently handles over 600 transactions per day.

HealWell24 has aggressive growth plans and is looking to raise Series A in the next two months. The startup had already raised a total of $1.1Mn from Seed and Its Pre-Series A Rounds.

The Accula System is an innovative platform that will accelerate the availability of reliable and accurate advanced molecular diagnostics at the point of care.

Mumbai (Maharashtra) [India], June 15: Thermo Fisher Scientific today announced the introduction of the new and innovative Accula SARS-CoV-2 Test that delivers gold-standard reverse transcription-polymerase chain reaction (RT-PCR) detection of SARS-CoV-2 in a point-of-care format.

The Accula SARS-CoV-2 Test has received Emergency Use Authorization (EUA) from the United States (U.S.) Food and Drug Administration (FDA) for the detection of SARS-CoV-2 in Clinical Laboratory Improvement Amendments (CLIA)–waived environments.

“Since the start of the pandemic, Thermo Fisher has acted quickly to provide support to the scientists and healthcare professionals at the frontlines of combating COVID-19,” said Amit Chopra, Managing Director, India, and South Asia, Thermo Fisher Scientific. “Thermo Fisher’s new testing platform combines the accuracy of RT-PCR with the simplicity, convenience, and procedural familiarity of traditional rapid immunoassays. The Accula SARS-CoV-2 Test is a natural extension to our existing offerings and will significantly help to meet the continuing demands for rapid and reliable COVID-19 testing in India.”

RT-PCR testing is streamlined from start to finish using a fully integrated, single-use microfluidic test cassette and the reusable, palm-sized Accula Dock. The test uses nasal swab samples and provides reliable, qualitative results in approximately 30 minutes. The Accula SARS-CoV-2 Test is enabled by proprietary PCR technology that allows for reduced absolute temperatures and reduced temperature differentials—resulting in rapid exponential amplification while reducing overall thermocycling times.

“The rapid Accula point-of-care test will open new avenues of personal and public testing without compromising on accuracy,” added Amit. “The introduction of the test in India is a demonstration of the impact our solutions have on human health during the pandemic, and far beyond.”

In January 2021, Thermo Fisher acquired Mesa Biotech Inc., which developed the Accula SARS-CoV-2 Test to provide accurate and faster results at the point of care.

For more information, please visit www.thermofisher.com

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner, and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies, or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

Pune (Maharashtra) [India], June 15: Cancer patients in India now have access to CURIA, a first-of-its-kind app developed by Swiss company OncoCoin AG, the most decentralized and equitable ecosystem of cancer information. CURIA, with a global community of over 150,000, empowers patients with individualised information on treatments, clinical trials, and experts. It provides them with the much-needed support to navigate the tough decisions throughout their treatment journey.

According to a report by WHO, 1 in every 10 Indians will develop cancer in their lifetime. There were as many as 1.16 million new cancer cases and 784,800 cancer deaths in 2018 alone. High mortality, combined with over 500 types of cancers, has generated a need for highly relevant information more than ever before.

CURIA empowers patients and their families with individualized information about approved therapies, clinical trials, and medical experts. Built over the OncoCoin platform, CURIA offers services such as tailored information, second opinion, and the opportunity to participate in research programmes. The timely availability of this information at patient’s fingertips helps them navigate through tough decisions throughout their treatment journey.

Speaking of this, Amit Ananpara, Innoplexus India Co-MD, said “Globally, 70% of cancer patients feel they do not get the information they need to make informed decisions. Specifically in India, limited knowledge of ongoing clinical trials leaves a gap in research involvement, stifling new insights. CURIA has successfully bridged such gaps in Europe. We look forward to helping cancer patients in India in their journey to cure.”

The tailored options in the app seek to answer three main questions which are often at the forefront of patients’ minds when they are diagnosed with cancer: ‘What are the treatment options available to me’, ‘What clinical trials could I participate in’, and ‘Who are the experts for my cancer type’. CURIA serves as a basis for patients to understand those options for their treatment journey, and to have more engaged discussions with their doctors about what’s right for them.

Adding further, Gunjan Bhardwaj, Founder & CEO, Innoplexus, said, “Cancer is one of the most common non-communicable diseases in India today. What exacerbates the situation further is the fact that there is a clear lack of information on the condition. We aim to bridge this gap through CURIA and enable individuals with this condition to connect with other cancer patients and share information.”

CURIA’s popular feature “Cancer Twin”, addresses patients’ need to connect with someone who really understands what they’re going through. The algorithm matches patients with the most similar other cancer profiles. They can share experiences through a private chat, anonymously. All conversations are encrypted through blockchain, bringing in the highest level of security to protect patient’s vital health information.

CURIA’s India launch follows successful launches in Germany, Italy, Spain, Switzerland, and France. It is available on Android and iOS platforms.

About Curia

CURIA is a mobile application developed by OncoCoin AG, a Swiss-based wholly-owned subsidiary of Innoplexus AG. OncoCoin, using its patented AI and blockchain technologies, structures trillions of data points from published and unpublished data. The information is tailored by parameters such as demographics, cancer type, stage, possible mutations, to generate the most relevant insights for quick decision making. The insights are fully regulated by a human team of experts. Curia was founded in June 2020 by Innoplexus AG and sits in Eschborn, Germany. The app is currently available in Germany, India, Italy, France, Spain, and Switzerland.

Jaipur (Rajasthan) [India], June 12: Dana Shivam Heart and Super-specialty hospital at Jaipur has started its vaccination drive for age over 18 at their hospital in Jaipur. As per the central govt guideline and instructions, hospital management is all prepared and set to deliver the vaccination doses.

Dr. Sunil Garssa informed the media today, “We are fully prepared and started our vaccination drive as per the govt. guidelines and are ready with full hands to fight and put an end to this pandemic through all measures including vaccination drive.”

“Vaccination is a key role player in this epidemic and if it is taken in time, it protects the user from the virus,” he added.

Covaxin by Bharat Biotech, a proudly Indian-made vaccine, is ready for the users at the hospital premise in Vidhyadhar Nagar. The effects and results of Covaxin are good. Dr. Sunil told that this vaccine is very effective in preventing infection and if infection occurs it will be of mild state and side effects are also negligible and mild.

As per Dr. Sunil, mild fever and tiredness may be experienced in some persons after vaccination, but hospital management has constructed a team of qualified personnel to properly follow up all the cases and assist them in fighting with these basic symptoms which may occur after the vaccination dose.  People don’t need to panic and this vaccination is a very important tool to fight this virus.

“As a Doctor myself, I disagree with the rumors about the effectiveness and side effects of the vaccine. I get regular inquiries on daily basis about these rumors and we always emphasize educating such inquiries by telling them the advantages of vaccination,” he says.

People still need to follow the basic Covid guideline of maintaining distance, eating healthy food, wearing a mask in public, regular hand wash and sanitization, whenever required.

Dana Shivam Hospital is a Multi Super Specialty hospital based at Vidhyadhar Nagar, Jaipur, and operating for the last 6 years successfully. During the covid pandemic, the hospital’s management and staff are regularly fighting on the frontline and have saved thousands of lives so far. The hospital provides services in Cardiology, Cardiac Surgery, Vascular Surgery, Neurosurgery, Gastroenterology, Urology, Gastro related surgeries, plastic surgery, Gynaecology, Intensive Care Unit, Orthopedic, and ENT surgeries. With a bed capacity of 100 and a medical staff strength of 180, they are operational 24 X 7 and prepared for any medical emergency too.

Dr. Sunil, who is the Director and Senior Consultant Cardiologist at Dana Shivam, has experience of successfully handling over 10,000 cases, particularly of acute heart attacks, with the helping hand of experienced Lab technicians and skilled Nursing staff. Multiple Trauma and Neurotrauma treatments are other expertise of Dana Shivam hospital.

For his contribution and efforts, Dr. Sunil Garssa has also been awarded as ‘Business Leader in Field of Medicine’ for the year 2019 by Honorable Chief Minister Mr. Ashok Gehlot.

Dana Shivam Hospital is completing 6 years of establishment and success this 17^th July. The hospital team comprises medical experts like Dr. Shalini Tomar Garssa, Dr. Rajvir Singh Garssa, Dr. CP Suthar, Dr. Subhash Doot, Dr. Kamlesh Agarwal, Dr. Sanjay Goyal, Dr. Sunita Choudhary, Dr. Govind Dubey, Dr. Nitin Gupta, Dr. BK Chhabra, Dr. Shravan Choudhary, and Dr. Sushila Choudhary and the management is handled by SP Yadav, Narendra Singh Somra and Hemant Dangi.